{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:49:02Z","timestamp":1761540542230,"version":"build-2065373602"},"reference-count":86,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3974,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:p>Prevention and management of acute coronary syndromes (ACS) are focal points of interest among health care providers. Acute coronary syndromes is an all\u2010encompassing term that refers to unstable angina, non\u2010Q wave myocardial infarction, and Q wave myocardial infarction. These syndromes are usually the result of atherosclerotic plaque rupture leading to thrombus formation in a coronary artery. Heparin and aspirin are traditional antithrombotic treatments. They typically are administered with antiischemic therapies and often with fibrinolytic agents for patients with ST segment elevation associated with acute myocardial infarction. Although aspirin and heparin are important, they have significant limitations that have prompted development of newer antithrombotic approaches. Adenosine diphosphate inhibitors have been evaluated as either alternatives or adjunctive treatment to aspirin. Glycoprotein IIb\u2010IIIa receptor inhibitors, low\u2010molecular\u2010weight heparins, and direct thrombin inhibitors have been studied as concurrent therapy with, or as alternatives to, heparin.<\/jats:p>","DOI":"10.1592\/phco.21.3.320.34211","type":"journal-article","created":{"date-parts":[[2004,6,7]],"date-time":"2004-06-07T08:04:29Z","timestamp":1086595469000},"page":"320-337","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Use of New Antithrombotic Therapies for Medical Management of Acute Coronary Syndromes"],"prefix":"10.1002","volume":"21","author":[{"given":"Barbara S.","family":"Wiggins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann K.","family":"Wittkowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean M.","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"volume-title":"2000 heart and stroke statistical update","year":"2000","author":"American Heart Association","key":"e_1_2_1_2_2"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201233260406"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00482-7"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03890.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/ajhp\/55.22.2363","article-title":"Glycoprotein IIb\u2010IIIa receptor antagonists in the management of cardiovascular diseases","volume":"55","author":"Chong P.H.","year":"1998","journal-title":"Am J Health-Syst Pharm"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.10.1193"},{"key":"e_1_2_1_9_2","first-page":"1244","article-title":"Adjunctive intracoronary thrombolysis in complicated angioplasty","volume":"31","author":"Crouch M.A.","year":"1997","journal-title":"Ann Pharmacother"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198308183090703"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198511283132201"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810273191701"},{"issue":"8607","key":"e_1_2_1_13_2","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS\u20102","volume":"2","author":"Second International Study of Infarct Survival Collaborative Group","year":"1988","journal-title":"Lancet"},{"issue":"7","key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.1980.03300330019023","article-title":"A randomized, controlled trial with aspirin in persons recovered from myocardial infarction","volume":"243","author":"Aspirin Myocardial Infarction Study Research Group","year":"1980","journal-title":"JAMA"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011223232101"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92336-G"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.1.81"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.611S"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.5.2045"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207163270301"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.489S"},{"key":"e_1_2_1_22_2","first-page":"21","article-title":"Targeted approaches to thrombus inhibition\u2014an end to the shotgun approach","volume":"20","author":"Topol E.J.","year":"1997","journal-title":"Clin Cardiol"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.5.1951"},{"issue":"5","key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V71.5.1366.1366","article-title":"Shear\u2010induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or usually large vWF multimers, requires adenosine diphosphate and is resistant to aspirin","volume":"71","author":"Moake J.L.","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90537-5"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/ajhp\/55.22.2402","article-title":"Unfractionated heparin in acute coronary syndromes: has its time come and gone?","volume":"55","author":"Trujillo T.C.","year":"1998","journal-title":"Am J Health-Syst Pharm"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400200027006"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-9-199311010-00002"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archinte.1995.00430050104011","article-title":"Appropriate use of heparin","volume":"155","author":"Gunnarsson P.S.","year":"1995","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370702"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1593"},{"issue":"122","key":"e_1_2_1_32_2","first-page":"782","article-title":"College of American Pathologist Conference XXXI on laboratory monitoring of anticoagulant therapy. Laboratory monitoring of unfractionated heparin therapy","author":"Olson J.D.","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-5-199809010-00009"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.6.2888"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040020-00006"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908243210804"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006153422402"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.9.806"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550010-00002"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.16.1597"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604253341702"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392303"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.20.2126"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.1993.tb00275.x"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.6.624"},{"key":"e_1_2_1_47_2","first-page":"263","article-title":"Rapid onset of inhibition of ADP induced platelet aggregation by a loading dose of clopidogrel [abstr]","volume":"17","author":"Bachmann F.","year":"1996","journal-title":"Eur Heart J"},{"issue":"3","key":"e_1_2_1_48_2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V88.3.907.907","article-title":"Analysis of GP IIb\u2010IIIa receptor number by quantification of 7E3 binding to human platelets","volume":"88","author":"Wagner C.L.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.9.2373"},{"volume-title":"ReoPro (abciximab) package insert","year":"1997","author":"Eli Lilly and Company","key":"e_1_2_1_50_2"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118859"},{"volume-title":"Integrilin (eptifibatide) package insert","year":"1998","author":"Key Pharmaceuticals","key":"e_1_2_1_52_2"},{"volume-title":"Aggrastat (tirofiban hydrochloride) package insert","year":"1998","author":"Merck & Co.","key":"e_1_2_1_53_2"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404073301402"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00128-2"},{"issue":"6","key":"e_1_2_1_56_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1997.03550060055036","article-title":"Long\u2010term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC investigator group. Evaluation of platelet IIb\u2010IIIa inhibition for prevention of ischemic complication","volume":"278","author":"Topol E.J.","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706123362401"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.15.1951"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10452-9"},{"issue":"9122","key":"e_1_2_1_60_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo\u2010controlled and balloon\u2010angioplasty\u2010controlled trial to assess safety of coronary stenting with use of platelet glycoprotein\u2010IIb\u2010IIIa blockade. Evaluation of platelet IIb\u2010IIIa inhibitor for stenting","volume":"352","author":"The EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2000.103743"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.21.2720"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1445"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382103"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382102"},{"key":"e_1_2_1_66_2","first-page":"3C","article-title":"New platelet glycoprotein IIb\/IIa inhibitor trials in percutaneous coronary intervention","volume":"11","author":"Topol E.J.","year":"1999","journal-title":"J Invest Cardiol"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(99)00171-0"},{"issue":"4","key":"e_1_2_1_68_2","doi-asserted-by":"crossref","first-page":"21B","DOI":"10.1016\/S0002-9149(97)00573-0","article-title":"Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrelin to minimize platelet aggregation and coronary thrombosis","volume":"80","author":"The IMPACT II Investigators","year":"1997","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1488"},{"issue":"4","key":"e_1_2_1_70_2","doi-asserted-by":"crossref","first-page":"34B","DOI":"10.1016\/S0002-9149(97)00575-4","article-title":"Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet glycoprotein IIb\u2010IIIa in unstable angina: receptor suppression using integrilin therapy","volume":"80","author":"The PURSUIT Investigators","year":"1997","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_71_2","unstructured":"ESPRIT Investigators.Enhanced suppression of platelet receptor glycoprotein IIb\/IIIa using integrilin therapy. ESPRIT trial [abstr]. Presented at the 49th annual scientific session of the American College of Cardiology Anaheim CA March 2 2000."},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371007"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)80001-W"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91270-2"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07350-X"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00487-6"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.17.1702"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1177\/107602969900500109"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00660-2"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509213331203"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609123351103"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00766-8"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.7.2155"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00663-8"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.3.769"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07332-2"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00107-2"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.3.320.34211","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.3.320.34211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:48:30Z","timestamp":1761054510000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.3.320.34211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1592\/phco.21.3.320.34211"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.3.320.34211","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2001,3]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}